Drug Profile
GEM 132
Alternative Names: Gene Expression Modulator 132Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Antisense DNA; Antivirals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cytomegalovirus infections; Cytomegalovirus retinitis